亿帆医药：截至2025年半年报公司实现营业收入26.35亿元

Core Insights - The company has been implementing a long-term strategy of "integration, innovation, and internationalization" since 2014, focusing on enhancing its core competitive advantages through increased R&D investment [2] - As of the 2025 semi-annual report, the company achieved a revenue of 2.635 billion yuan, with approximately 2.254 billion yuan, or 85.53%, coming from pharmaceutical-related revenues [2] Company Strategy - The company emphasizes maintaining its existing business while continuously innovating and upgrading its operations [2] - The primary industry development direction remains focused on pharmaceutical formulations and active pharmaceutical ingredients [2]